![](jpg/stat_alnylam03-645x645.jpg)
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a look at pharma’s struggle to make inroads in D.C., the curious story of the latest FDA drug approval, and a twist on the year’s biggest biotech event. One more thing: We’ll be taking off Monday for Presidents’ Day, but this newsletter will be back in your inbox bright and early Tuesday morning.
The need-to-know this morning
- Sarepta Therapeutics said the FDA accepted its follow-0n application seeking full approval and expanded use of Elevidys, a gene therapy for Duchenne muscular dystrophy. The agency’s decision date is June 21.
Has PhRMA lost its fangs?
Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect